Therapy Areas: Respiratory
Ethris names Thomas Langenickel, MD as CMO
3 June 2019 -

mRNA therapeutics company Ethris GmbH announced on Monday the appointment of Thomas Langenickel, MD as its new chief medical officer.

Most recently, Dr Langenickel has served as executive director and head of Respiratory Profiling within the Translational Medicine Group at Novartis AG.

Previously, Dr Langenickel has held positions of increasing responsibility in Discovery Medicine at Bristol Myers Squibb.

Dr Langenickel will guide the company's first drug candidate ETH42 into development as well as support further activities to build a pipeline of transcript therapies for pulmonary disorders, commented CMO Thomas Langenickel. It is developing a portfolio of SNIM RNA therapies for genetic respiratory ciliopathies as well as researching SNIM RNA therapies for treatment of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis exclusively with AstraZeneca.

Login
Username:

Password: